跳至主要内容
临床试验/NCT07665073
NCT07665073尚未招募4 期

Risperidone vs Cariprazine in Acute Mania a Head to Head Comparison of Efficacy vs Tolerability

Pakistan Institute of Medical Sciences0 个研究点目标入组 50 人开始时间: 2027年6月1日最近更新:

试验速览

阶段
4 期
状态
尚未招募
入组人数
50

研究概览

简要总结

Randomized, double-blind, parallel-group study comparing efficacy and safety of Risperidone versus Cariprazine in adults with acute manic episodes. Participants will receive oral study drug for 6 weeks. Primary outcome is change in YMRS total score from baseline to week 6.

详细描述

This is a randomized, double-blind, active-controlled, parallel assignment clinical trial conducted at Pakistan Institute of Medical Sciences, Islamabad. Adults aged 18-65 with ICD 11 diagnosis of Bipolar I Disorder, current episode manic, will be randomized 1:1 to receive Risperidone or Cariprazine for 6 weeks. The study aims to compare reduction in mania symptom severity and tolerability between the two antipsychotics. Assessments include YMRS, UKU and safety parameters at baseline, week 3, and week 6.'

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • patients with bipolar mania Age 18-60 YMRS>20 -

排除标准

  • Patients with substance use Patients already taking antipsychotics Secondary mood disorder

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Maera Hussain

Resident psychiatrist Pims

Pakistan Institute of Medical Sciences

相似试验